|
| The open label, phase 3 PALLAS trial randomized 5600 patients with stage II to III hormone receptor positive, HER2 negative breast cancer 1 1 to receive either the CDK4 6 inhibitor palbociclib Ibrance orally at 125 mg daily on a 3 weeks on 1 week off schedule for 2 years plus endocrine therapy n 2883 or endocrine therapy alone n 2877, which consisted of an aromatase inhibitor or tamoxifen, with or without a luteinizing hormone releasing hormone agonist <a href=https://fastpriligy.top/>priligy tablets</a> |
|
|
